Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

A novel strain of human coronaviruses, named by the International Committee on Taxonomy of Viruses (ICTV) as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged and caused an infectious disease. This disease has recently been referred to by the World Health Organisation (WHO) as the “coronavirus disease 2019” (COVID-19). Since the first report of this disease in December 2019 in Wuhan, China, COVID-19 has aggressively spread across the globe. WHO declared it a pandemic on March 11.

ARIA and EAACI followed the example of the Dutch ENT Society and sent a questionnaire to all ARIA members regarding the recommendations for allergic rhinitis and anosmia. ARIA and EAACI are proposing a joint statement following the results of the questionnaire.

(ARIA-EAACI consensus document. Allergy. 2020;75(10):2440-2444)